$ 0.89
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of OTLK is 7.9 and suggests 790% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
